New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracyte’s Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer
28 Setembro 2023 - 5:05PM
Business Wire
Company also introduces research-use-only
Afirma Genomic Resource for Intelligent Discovery (GRID) platform
for additional insights into thyroid nodules and cancer
Veracyte, Inc. (Nasdaq: VCYT) today announced that new data
presented at the 2023 American Thyroid Association (ATA) Annual
Meeting demonstrate the type of novel molecular insights for
thyroid nodules and cancer that are enabled by analysis with the
Afirma Genomic Sequencing Classifier (GSC). Presented by clinical
researchers in three posters, the findings are based on Afirma
whole-transcriptome RNA sequencing data and reveal novel molecular
profiles to advance research of thyroid nodules and cancer. These
data represent findings that can be assessed utilizing the
company’s Afirma Genomic Resource for Intelligent Discovery (GRID)
tool, which will soon be available, upon request, on a
research-use-only basis.
“These ATA presentations underscore the value of personalized,
whole-transcriptome-based data for a clearer understanding of the
molecular underpinnings of thyroid nodules and cancer, which may
ultimately be useful for more tailored treatment of patients,” said
Joshua Klopper, M.D., Veracyte’s medical director for
Endocrinology. “Now with the Afirma GRID, we are pleased to give
researchers a new tool to help fuel novel discoveries in the
science of thyroid nodules and cancer.”
The three ATA posters include results from the analysis of
whole-transcriptome data derived from the Afirma GSC. Highlights
from the posters include:
- Leveraging RNA Sequencing for Pre-Operative
Immunophenotyping of BRAFV600E+ Thyroid Nodules Jarod Olay,
M.S., from the UCLA David Geffen School of Medicine and
collaborators found that RNA expression profiles derived by Afirma
GSC molecular testing may allow for pre-operative immunophenotyping
of thyroid cancers instead of the traditional immunohistochemistry
performed on surgical specimens. Their study was based on a
retrospective analysis of nearly 48,000 thyroid nodules analyzed
with the Afirma GSC, confirming that the classifier identified the
expected immunophenotype for a specific type of thyroid cancer
molecular alteration. While additional research is needed, these
findings begin to suggest the potential future use of Afirma GSC
testing to predict a thyroid cancer’s response to immune checkpoint
inhibitor therapy.
- Molecular Assessment of Isthmus Thyroid Carcinomas Sina
Jasim, M.D., from Washington University in St. Louis and
collaborators detected molecular differences between thyroid
cancers in the isthmus compared to lobar locations, which could
help explain why thyroid nodules in the isthmus are more likely to
be malignant and demonstrate aggressive behavior. Analysis with
Afirma GSC revealed that isthmus-based cancers had increased
BRAF-like molecular signatures, ERK, and FMT (follicular
mesenchymal transition) signaling compared to lobar-based
cancers.
- Sodium Iodide Symporter (NIS) Expression in Cytologically
Indeterminate and Malignant Thyroid Nodules Prasana Santhanam,
M.B.B.S., M.D., from the Johns Hopkins University School of
Medicine and collaborators found that NIS expression varies widely
across thyroid nodule cytological classification groups and across
molecular alterations. They analyzed Afirma GSC gene expression
data from more than 47,000 thyroid nodules and recommend follow-up
studies to determine how pre-operative assessment of NIS expression
could be used to improve treatment selection for patients.
“Understanding the broad range of molecular profiles associated
with thyroid cancer will require sophisticated analysis tools and
studies to determine how these profiles can potentially be used to
stratify patients and identify the best course of treatment,” said
Dr. Santhanam. “Our team was pleased to collaborate with the Afirma
team for whole-transcriptome analysis of thyroid FNA samples and to
gain new insights into the spectrum of NIS expression.”
New Research-Use-Only Afirma GRID
The three molecular signatures identified in these studies,
along with many other thyroid cancer molecular profiles, will soon
be available through the new Afirma GRID research-use-only tool.
The database was developed through novel discovery work at Veracyte
and through the utilization of published literature. It is designed
to serve as a comprehensive resource for research into molecular
characteristics that may ultimately help improve the understanding
of how to manage patients with thyroid nodules. The tool is
available upon request and is intended for use on a
research-use-only basis for thyroid nodules that are deemed
suspicious for cancer by the Afirma GSC or are reported as Bethesda
V or VI by cytopathology.
“We are excited to soon make this new tool available to the
thyroid cancer research community,” said Dr. Klopper. “Similar to
what Veracyte has done for prostate cancer research with our
Decipher GRID tool, with Afirma GRID we aim to help usher in a new
era of more personalized diagnosis and treatment for patients with
thyroid nodules and cancer.”
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company whose
vision is to transform cancer care for patients all over the world.
We empower clinicians with the high-value insights they need to
guide and assure patients at pivotal moments in the race to
diagnose and treat cancer. Our high-performing tests enable
clinicians to make more confident diagnostic, prognostic, and
treatment decisions for some of the most challenging diseases such
as thyroid, prostate, breast, bladder and lung cancers, as well as
interstitial lung diseases. We help patients avoid unnecessary
procedures and speed time to diagnosis and appropriate treatment.
In addition to making our tests available in the U.S. through our
central laboratories, we also aim to deliver our tests to patients
worldwide through a distributed model to laboratories that can
perform them locally. For more information, please visit
www.veracyte.com and follow the company on Twitter (@veracyte).
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to our statements related to our plans,
objectives, expectations (financial and otherwise) or intentions
with respect to our clinical tests in and outside of the United
States. Forward-looking statements can be identified by words such
as: “appears,” "anticipate," "intend," "plan," "expect," "believe,"
"should," "may," "will," “positioned,” “designed” and similar
references to future periods. Examples of forward-looking
statements include, among others, that the Afirma GRID can help
enable clearer understanding of the molecular underpinnings of
thyroid nodules and cancer, which may ultimately be useful for more
tailored treatment of patients with cancer; the Afirma GRID can
help researchers fuel novel discoveries in the science of thyroid
nodules and cancer; Afirma GSC testing may have potential in the
future to predict a thyroid cancer’s response to immune checkpoint
inhibitor therapy. Additional factors that may impact these
forward-looking statements can be found under the caption “Risk
Factors” in our Annual Report on Form 10-K filed on March 1, 2023,
and our Quarterly Report on Form 10-Q filed for the three months
ended June 30, 2023. Copies of these documents, when available, may
be found in the Investors section of our website at
https://investor.veracyte.com. These forward-looking statements
speak only as of the date hereof and, except as required by law, we
specifically disclaim any obligation to update these
forward-looking statements or reasons why actual results might
differ, whether as a result of new information, future events or
otherwise.
Veracyte, the Veracyte logo and Afirma are registered trademarks
of Veracyte, Inc. and its subsidiaries in the U.S. and selected
countries.
Veracyte delivers the Afirma Genomic Sequencing Classifier and
TERT DNA analysis from its CLIA laboratory. These tests are not
CE-IVD marked and have not been cleared or approved by the FDA;
their performance characteristics were determined by Veracyte and
they might be considered for Research Use Only in some markets.
Please contact Veracyte for confirmation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230928531630/en/
Investors: investors@veracyte.com 619-393-1545
Media: Tracy Morris VP of Global Corporate Communications
tracy.morris@veracyte.com 650-380-4413
Veracyte (NASDAQ:VCYT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Veracyte (NASDAQ:VCYT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024